Elezanumab
- Generic Name
- Elezanumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1791416-49-3
- Unique Ingredient Identifier
- SK1LVT23A1
- Background
Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).
- Associated Conditions
- -
- Associated Therapies
- -
Spinal Cord Injury Clinical Trials 2024: EMA, PDMA, FDA
DelveInsight's 'Spinal Cord Injury Pipeline Insight, 2024' report details 35+ therapies in development by 35+ companies, including Athersys, Olatec Therapeutics, and AbbVie, focusing on mechanism of action, clinical trials, and market prospects. Key therapies include Allogeneic stem cell therapy, OLT1177, and Elezanumab, with ongoing trials and potential market impact. The report covers pre-clinical to marketed phases, regulatory approvals, and market dynamics.
Ischemic Stroke Drug Pipeline Research Report 2024
The 'Ischemic Stroke - Pipeline Insight, 2024' report by ResearchAndMarkets.com offers insights into 50+ companies and 55+ pipeline drugs for ischemic stroke, covering drug profiles, therapeutic assessments, and pipeline development activities. Key drugs include Nelonemdaz (GNT Pharma), 3K3A-APC (ZZ Biotech), JX10 (JIXING Pharmaceuticals), Elezanumab (AbbVie), and UMC119-06 (Meridigen Biotech Co., Ltd.), all in various stages of clinical development. The report highlights trends, collaborations, and the latest developments in ischemic stroke therapeutics.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath